Journal
ADVANCED HEALTHCARE MATERIALS
Volume 11, Issue 23, Pages -Publisher
WILEY
DOI: 10.1002/adhm.202201655
Keywords
blood-brain barrier; brain drug delivery; gene therapy; Parkinson's disease; polydopamine
Funding
- National Natural Science Foundation of China [31370967]
- Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme, China
- Science and Technology Planning Projects of Guangdong Province, China [2022A1515010914]
- Open Research Funds of the State Key Laboratory of Ophthalmology, China
- Science and Technology Project of Guangzhou, China [202201010608]
Ask authors/readers for more resources
In this study, MgOp@PPLP nanoparticles were developed to overcome the blood-brain barrier and be used for gene therapy and antioxidant therapy in Parkinson's disease. These nanoparticles showed good neuroprotective effects in PD models.
The blood-brain barrier (BBB) is a major limiting factor that prevents the treatment of Parkinson's disease (PD). In the present study, MgOp@PPLP nanoparticles are explored by using MgO nanoparticles as a substrate, polydopamine as a shell, wrapping anti-SNCA plasmid inside, and modifying polyethylene glycol, lactoferrin, and puerarin on the surface to improve the hydrophilicity, brain targeting and antioxidant properties of the particles, respectively. MgOp@PPLP exhibits superior near-infrared radiation (NIR) response. Under the guidance of photothermal effect, these MgOp@PPLP particles are capable of penetrating the BBB and be taken up by neuronal cells to exert gene therapy and antioxidant therapy. In both in vivo and in vitro models of PD, MgOp@PPLP exhibits good neuroprotective effects. Therefore, combined with noninvasive NIR radiation, MgOp@PPLP nanoplatform with good biocompatibility becomes an ideal material to combat neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available